Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease

Immune checkpoint inhibitors (ICIs) have revolutionised the field of oncology. While most ICIs are well-tolerated, severe and fatal immune-related adverse events (irAEs) have been documented, likely related to the strengthened immunity harnessed by ICIs against tumours. Endocrinopathies are some of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chau, Charlene Y. C., Shih, Kendrick C., Chow, Loraine L. W., Lee, Victor H. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886920/
https://www.ncbi.nlm.nih.gov/pubmed/33146864
http://dx.doi.org/10.1007/s40123-020-00317-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886920/
https://www.ncbi.nlm.nih.gov/pubmed/33146864
http://dx.doi.org/10.1007/s40123-020-00317-y

Ejemplares similares